Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

ICON Launches New Medical Imaging Solution for Early Phase Trials

Published: Thursday, October 25, 2012
Last Updated: Thursday, October 25, 2012
Bookmark and Share
Streamlined early phase offering designed to support faster decision making.

ICON plc, has announced the launch of a new medical imaging solution tailored to the unique requirements of early phase trials.

This new solution incorporates streamlined processes and procedures to maximize the information collected from image data and to ensure that this information is processed rapidly in line with the shorter timelines and requirements of early-phase research.

Enhanced decision making is then enabled by MIRA™, ICON’s image management system, which standardizes data from all imaging formats and allows for centralized analysis and interpretation of data.

Driving this innovation is a team of scientific and regulatory experts with deep imaging and early-phase experience to help sponsors make critical decisions about their compounds faster.

“PET, volumetrics, advanced CT and MRI are increasingly being used in early phase research which has created a demand for more tailored imaging solutions for early phase trials,” commented Ted Gastineau, President, ICON Medical Imaging.

Gastineau continued, “We have developed a unique and cost-effective solution that provides true insight to the data generated from imaging technologies and helps clients decide earlier about the future success of a drug.”

ICON Medical Imaging’s early phase group will be led by Dr. James Conklin, Senior Vice President, Medical and Scientific Affairs and Dr. Valerie Treyer, Director, Medical and Scientific Affairs, who together bring over 45 years of experience in the management of medical image data used in clinical trials.

The group will work closely with ICON Development Solutions which provides a full range of early-phase services, including clinical pharmacology, bioanalytical, PK/PD modelling and simulation, and Clinical Pharmacodynamic Models for early indications of drug efficacy.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More Than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

ICON to Acquire ClinicalRM
The acquisition will enhance ICON’s ability to access the market for government sponsored research and further enhances its capabilities in the areas of vaccines and infectious disease.
Friday, July 08, 2016
Icon Selected By Genomics England to Support the Largest Genome Sequencing Project
Company has announced that it has been selected by Genomics England to support the largest genome sequencing project of its kind for cancer and rare diseases.
Wednesday, February 17, 2016
ICON Acquires PMG Research Inc.
Acquisition enhances ICON’s site and patient engagement capabilities.
Tuesday, December 15, 2015
ICON Partners with iCardiac Technologies
ICON certified as a partner of iCardiac’s early precision QT® program.
Saturday, November 07, 2015
ICON Creates New Global Innovation Hub in Ireland
Global Innovation Hub will create 200 Scientific, IT and Business jobs in Ireland.
Thursday, February 05, 2015
ICON Selected by the FDA to Develop New PRO Measure for HABP Trials
New PRO measure being developed in conjunction with the FNIH Biomarkers Consortium.
Thursday, November 13, 2014
ICON Launches New Analytics Service for Advanced Medical Review of Laboratory Data
ICONIK Labs allows visualization, analysis and reporting on laboratory data in real time.
Tuesday, November 19, 2013
ICON Announces Appointment to Board of Directors
ICON plc today announced the appointment of Professor William Hall as a non-executive director.
Friday, February 22, 2013
ICON to Acquire Clinical Trial Services Division of Cross Country Healthcare Inc
Acquisition expands ICON’s global resourcing, FSP and safety capabilities.
Thursday, February 07, 2013
ICON Selected by Shire as Global Strategic Partner
Global strategic partner for clinical research and central laboratory services.
Monday, January 23, 2012
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
JPK NanoWizard® Applied to a Wide Range of Research
The NanoWizard® AFM from JPK is applied for interdisciplinary research at the University of South Australia for applications including smart wound healing and how plants can protect themselves from toxins.
Mutations in DNA-Repair Genes Found in Advanced Prostate Cancers
New findings indicate that nearly 12% of male advanced prostate cancer sufferers have inherited mutation in DNA-repair genes.
Protein Boosts Rice Yield by 54%
Over-expression of a natural protein in rice plants led to a 54% increase in crop yield and 40% increase in nitrogen-use efficiency.
Ice Bucket Challenge Instrumental in Gene Discovery
Donations from the ALS Ice Bucket Chellenge allowed for the largest-ever study of inherited ALS, which identified a new ALS gene.
Genetic Variability in Cell Bank Lots
Researchers working with cancer cells from the same cell bank acquired at the same time, found that the cells were genetically different.
Triple-Action Therapy Patch Shows Promise
Patch that delivers drug, gene, and light-based therapy to tumor sites shows promising results in mice.
Soil Nitrogen Age Important for Precision Agriculture
Calculating the age of nitrogen in corn and soybean fields could lead to improved fertilizer application techniques.
Targeting Autoimmunity
Researchers have developed a strategy to treat a rare autoimmune disease which could lead to treatments of other autoimmune diseases.
Molecule May Affect Gaucher, Parkinson's Disease
Research has identified a molecule that restores activity of a dysfunctional enzyme linked to Gaucher and Parkinson's disease.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!